17 July 2018 | News
The study was conducted by researchers who are either consultants to RegeneRx or, employees of, or consultants to GtreeBNT/ReGenTree LLC, a RegeneRx licensee for RGN-259 in North American and certain Asian territories
RegeneRx Biopharmaceuticals, or "RegeneRx", a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES).
In the study, researchers demonstrated that after ten days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasis®), lifitegrast (Xiidra®), and diquafosol (Diquas®).
The study parameters measured were tear production, corneal smoothness, and decreased fluorescein staining, among others.
Corneal epithelial detachment, conjunctival goblet cells, mucin production, and expression of inflammatory factors were also evaluated.
RGN-259 was equal to or better than the three other approved products in each case. In conclusion, the authors stated that, "RGN-259 promoted recovery of mucins and goblet cells, improved corneal integrity, and reduced inflammation in a dry eye mouse model and was equal to or more effective than prescription treatments."
The study was conducted by researchers who are either consultants to RegeneRx or, employees of, or consultants to GtreeBNT/ReGenTree LLC, a RegeneRx licensee for RGN-259 in North American and certain Asian territories.
RGN-259 is currently in Phase 3 clinical trials in the U.S. and been studied in approximately 1,000 patients.
In addition to the reported rapid onset of clinical efficacies, RGN-259 has not reported any significant side effects compared to other products currently approved for DES.